A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus.
Phase of Trial: Phase II
Latest Information Update: 27 May 2016
At a glance
- Drugs CC 11050 (Primary)
- Indications Cutaneous lupus erythematosus; Discoid lupus erythematosus
- Focus Adverse reactions; Pharmacokinetics
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Mar 2012 Actual initiation date changed from Feb 2011 to Oct 2010 as reported by ClinicalTrials.gov.
- 05 Mar 2012 Additional lead trial investigator (Tong Li) identified as reported by ClinicalTrials.gov.